Protea Biosciences Group, Inc. (“Protea”), a leading bioanalytics innovator, announced today that Stephen Turner, the company’s CEO, will present at the 9th Annual Lazard Healthcare Conference on Wednesday November 14th, at the Pierre Hotel in New York City. Protea will join a select group of private healthcare companies that have been invited to present at the Lazard Healthcare Conference.
“We are pleased to have this opportunity to present Protea, and our groundbreaking LAESI technology platform, to the institutional investment community at this year’s Lazard Healthcare Conference,” stated Stephen Turner, Protea’s CEO. “Protea is building a new life science franchise by developing and marketing technology that allows biologists to obtain full biomolecular imaging data on their tissue, cell or biofluid samples in their native state, without sample preparation. For the first time, researchers can obtain mass spectrometric data on live cells and bacterial cell colonies, with results available in the same day.”
Protea’s proprietary LAESI (Laser Ablation Electrospray Ionization) technology allows two and three dimensional distribution profiles of molecules in biological samples for unambiguous drug/target interaction studies, as well as the study of bio-dynamics directly from living cells. Using LAESI mass spectrometry, large numbers of biomolecules can be rapidly identified and spatially mapped to cell structures, tissues, and fluids.
More information about the upcoming conference can be found at: http://www.lazardcap.com/conferenceDocs/7041_2012%20Lazard%20Capital%20Markets%20Healthcare%20Conference%20Invitation.pdf
About Protea Biosciences Group, Inc.
Protea is a leader in the field of bioanalytics — the identification and characterization of proteins, metabolites, and other biomolecules, which are the products of all living cells and life forms — technology that is foundational for all pharmaceutical and life science research.
